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A B S T R A C T
In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may
provide a suitable adjunct to enhance eﬃcacy of chemotherapy in models of colorectal cancer. However,
the majority of evidence for this currently derives from established cell lines.
Here, we utilised patient-derived colorectal liver metastases (CRLM) to assess whether curcumin may
provide added beneﬁt over 5-ﬂuorouracil (5-FU) and oxaliplatin (FOLFOX) in cancer stem cell (CSC) models.
Combination of curcumin with FOLFOX chemotherapy was then assessed clinically in a phase I dose es-
calation study. Curcumin alone and in combination signiﬁcantly reduced spheroid number in CRLM CSC
models, and decreased the number of cells with high aldehyde dehydrogenase activity (ALDHhigh/
CD133−). Addition of curcumin to oxaliplatin/5-FU enhanced anti-proliferative and pro-apoptotic effects
in a proportion of patient-derived explants, whilst reducing expression of stem cell-associated markers
ALDH and CD133. The phase I dose escalation study revealed curcumin to be a safe and tolerable adjunct
to FOLFOX chemotherapy in patients with CRLM (n = 12) at doses up to 2 grams daily.
Curcumin may provide added beneﬁt in subsets of patients when administered with FOLFOX, and is
a well-tolerated chemotherapy adjunct.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Twenty-ﬁve percent of patients diagnosed with colorectal cancer
present with metastatic disease [1], with the liver being the pre-
dominant site for metastatic spread. Approximately 50% of colorectal
cancer (CRC) patients have liver metastases either at primary di-
agnosis or following disease recurrence [2]. Surgical resection, where
possible, is the only potentially curative option in locally recur-
rent disease or metastatic disease localised to the liver or lungs.
However, the majority of patients are not suitable for surgery and
receive palliative treatment using multi-agent chemotherapy with
or without biological agents.
Addition of experimental agents into standard care chemother-
apy (5-FU, oxaliplatin, folinic acid (FOLFOX)) is often accompanied
by an increase in debilitating side effects. Oxaliplatin-based che-
motherapy results in acute and chronic peripheral neuropathies
which are frequently dose-limiting, leading to early treatment ces-
sation or treatment de-escalation protocols. Consequently, treatment
eﬃcacy is likely to be compromised. Increasingly, pre-clinical
evidence suggests that there may be a role for low-toxicity, dietary-
derived agents in enhancing eﬃcacy or reducing chemotherapy-
induced side effects. One such agent which has been investigated
extensively for chemopreventive and therapeutic effects in colorectal
cancer is the polyphenol, curcumin, a constituent of the spice tur-
meric [3–6]. Clinical trials utilising curcumin in an oncology setting
have targeted several disease sites including colorectal [5,7–11], pan-
creatic [12–15], breast [16], and haematological malignancies [17,18],
in addition to being investigated for its ability to alleviate therapy-
induced toxicities such as radiation dermatitis [19,20]. Whilst these
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are generally small, phase I/II trials, the favourable toxicity proﬁle
of curcumin combined with limited evidence that certain subsets
of patients may derive beneﬁt from its addition to interventional
regimens warrants further investigation. These studies have also
alluded to pharmacodynamic changes which may bear relevance
to the carcinogenic process. In colorectal cancer, this includes de-
creased leukocyte prostaglandin E2 levels [11], reduced levels of the
oxidative DNA adduct M1G in malignant tissue [8], reduction in the
number of aberrant crypt foci [7], and up-regulation of p53 in tumour
tissue [10]. In pancreatic cancer, curcumin was found to down-
regulate Nuclear Factor kappa B (NFκB), cyclo-oxygenase 2(COX-2)
and phosphorylation of Signal Transducer and Activator of Tran-
scription 3 (STAT-3) in peripheral blood mononuclear cells [12],
whilst a decrease in nitric oxide was observed in chronic myeloid
leukaemia patients [17].
Further to these published studies, there are currently 13 ac-
tively recruiting oncology-based trials using curcumin as an
investigational agent registered on clinicaltrials.gov.
More recent evidence suggests that curcumin may be able to
target cancer stem-like cells (CSCs) [21–23]. It has been postu-
lated that the CSC component of tumours contributes to decreased
eﬃcacy of chemotherapy, and may ultimately be responsible for
tumour recurrence and metastatic spread. These cells have the ca-
pacity for self-renewal, differentiation, invasion and metastasis, and
are thought to have a higher degree of innate or acquired chemo-
resistance [24,25]. Thus failure to eradicate these cells may ultimately
be responsible for disease progression.
In the study described here, ex-vivomodels derived from human
colorectal liver metastases were utilised to test the hypothesis that
addition of curcumin to FOLFOX chemotherapy enhances eﬃcacy,
with the potential to target cancer stem-like cells. Despite growing
evidence suggesting curcuminmay be able to augment FOLFOX che-
motherapy, this combination has never been tested clinically.
Therefore, here we also describe, for the ﬁrst time, a dose escala-
tion study combining curcuminwith ﬁrst line FOLFOX chemotherapy
in patients with CRLM.
Materials and methods
Laboratory methods
Collection and processing of tumour samples
Tumour samples were obtained from patients undergoing surgical resection for
colorectal liver metastases at University Hospitals of Leicester NHS Trust. Ethical ap-
proval for this fully anonymised, excess tissue study was granted by Leicestershire,
Northamptonshire and Rutland Ethics Committee (REC reference 09/H0402/45).
Tissues were processed as previously described [26]. Stem-like and epithelial
components were characterised by ﬂow cytometry (FACS Aria II, Becton Dickinson,
Oxford, UK) using antibodies directed against epithelial cellular adhesion mole-
cule (EPCAM), CD133, CD26 and aldehyde dehydrogenase activity.
Maintenance of tumours and sphere growth
Tumour tissues were maintained by serial passage through Non Obese Diabet-
ic Severe Combined Immunodeﬁcient Mice (NOD-SCID) mice [26]. All experiments
were carried out under project license PPL 80/2167, granted to Leicester University
by the United KingdomHome Oﬃce, vetted by Leicester University Local Ethical Com-
mittee for Animal Experimentation and met the standards required by the UKCCR
for animal welfare. Following serial passage, part of the tumour tissue was colla-
genase digested for ﬂow cytometric proﬁling and assessment of spheroid formation,
and a portionwas formalin-ﬁxed and paraﬃnwax-embedded. Spheroids were treated
with pharmacologically relevant concentrations of agents as follows: DMSO, 5 μM
curcumin, 2 μM oxaliplatin + 5 μM 5-FU and 5 μM curcumin + 2 μM oxaliplatin + 5 μM
5-FU. Following a period of 2 weeks (representing 1 cycle of chemotherapy), spher-
oids were harvested for FACS analysis, spheroid counts and size using a Nikon TE
2000 U camera system with Eclipse software (Surrey, UK). A pluripotent stem cell
protein proﬁler array kit (R&D Systems, Oxfordshire, UK) was used to further de-
termine treatment-induced effects on the stem cell compartment.
Explant culture
Six-well plates and inserts (0.4 μm, Millipore, Watford, UK) were equilibrated
at 37 °C, 5% CO2, with 1.5mL of media/well (DMEM, 1% FCS and antibiotic/antimycotic).
Tumour tissue was cut (1 mm [3]), 9 segments randomly allocated per well, placed
on top of the inserts and incubated for 15 h. Media containing appropriate treat-
ments were added and tissues incubated for a further 24 h prior to formalin ﬁxation/
paraﬃn embedding. Immunohistochemistry was undertaken using the Novolink
Polymer Detection as per manufacturer’s instructions, and the following markers
were assessed: Ki67, cleaved caspase-3 (quantitative assessment), ALDH1A1, CD133,
CD26, Nanog, XRCC1, ERCC1, MLH1, MSH2, MSH6 (semi-quantitative assessment
via a trained pathologist). Scoring was undertaken blinded to the treatment
groups.
Clinical methods – phase I dose escalation study to assess safety, tolerability and
feasibility of administering oral curcumin during standard FOLFOX chemotherapy
for palliation of colorectal liver metastases (ClinicalTrials.gov:NCT01490996)
Ethical approval was obtained from the Nottingham Research Ethics Commit-
tee 1 (REC reference 11/EM/0263). Target populations were patients presenting with
histological diagnosis of metastatic colorectal cancer suitable for palliative FOLFOX-
based chemotherapy. The Trial schema is shown in Supplemental data S1, and full
details of the trial protocol in accordance with the SPIRIT statement [27] can be found
in Ref. 28. In brief, the ﬁrst tier of participants was recruited to receive 500 mg
(1 capsule) of oral curcumin C3-complex daily, 7 days prior to the scheduled che-
motherapy. If no curcumin-induced toxicities (CIT) were observed, daily oral curcumin
was continued once chemotherapy commenced. FOLFOX-based chemotherapy con-
sisted of 2-weekly cycles of chemotherapy given to a maximum of 12 cycles or until
withdrawal from the trial. Once no CITs were observed in the ﬁrst tier of patients
following completion of two cycles of chemotherapy, recruitment to the next es-
calation dose of 1 g (2 capsules) daily and then 2 g (4 capsules) commenced. Side
effects were classiﬁed using the Common Terminology Criteria for Adverse Events
(CTC-AE) version 4, with further data captured using a validated neurotoxicity ques-
tionnaire and pre/post trial questionnaires to capture demographics and concerns
regarding curcumin consumption.
Results
Effect of curcumin combined with 5-FU + oxaliplatin in spheroid
models of CRLM
Spheroids derived from ﬁve different patient CRLM xenografts
were incubated for 2 weeks with either oxaliplatin + 5-FU alone or
in combination with curcumin. Treatments decreased spheroid
numbers compared to control (Fig. 1A,C), but signiﬁcance was only
reached with the triple combination, reducing spheroid number by
~80% (Supplemental data S2). The ALDHhigh/CD133− population was
obliterated by oxaliplatin + 5-FU alone and by the triple combina-
tion (Fig. 1B), but there were no signiﬁcant differences in the
populations. In one sample (in which high ALDH activity was as-
sociated with aggressive spheroid growth without prior passage),
curcumin alone decreased the ALDHhigh/CD133− population to a
greater extent than oxaliplatin + 5-FU (Fig. 1D). Exposure of spher-
oids to the triple combination signiﬁcantly downregulated expression
of pluripotent stem cell markers Oct3-4, AFP and HNF/FoxA2 at 24
hours, and Nanog, Otx2 and VEGFR2 at 72 hours (Fig. 1E).
Effect of curcumin combined with 5-FU + oxaliplatin on stem cell
markers in explant cultures of CRLM
Explant cultures of patient-derived tissues were exposed to
oxaliplatin + FU alone or in combination with curcumin. Stem cell
markers were assessed immunohistochemically, and staining in-
tensity graded in comparisonwith cultures treatedwith eitherDMSO
or oxaliplatin + 5-FU. ALDH1A1 stainingwas decreased by curcumin
alone and oxaliplatin + 5-FU in 4/10 or 2/10 explants, respectively
(Table 1). In cultures exposed to curcumin + oxaliplatin expression
of ALDH1A1 or CD133 was inhibited in 3/10 or 4/9 samples, re-
spectively, compared to staining in tissues exposed to oxaliplatin + 5-
FU. Expressionof bothCD26andNanog remained relatively refractory
to treatment, with only the triple combination decreasing CD26 in
2/10 samples.
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Fig. 1. The effects of combinations of curcumin, oxaliplatin and 5-FU on spheroids and stem cell markers, from single cells derived from serial passage of CRLM tissue in
NOD-SCID mice (A–C, E) or directly from CRLM without passage (D). (A) Spheroid number after treatment, represented as a percentage of the DMSO control, N = 5 (each
replicate is a different patient sample). (B) Flow cytometric data as a percentage of the EpCAM+ population in spheroids from (A) ±SEM, N = 5. (C) Representative light mi-
croscopy of spheroids after treatment. Circles highlight examples of spheroids. (D) Flow cytometry of spheres derived from 1 patient sample over 3 passages. (E) Spheroids
were treated for 24 or 72 hours. Expression is represented as a percentage of DMSO as determined by densitometry. Mean ± SEM, N = 3, * P ≤ 0.05, ** P ≤ 0.001 compared to
DMSO.
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Effect of curcumin on Ki67 and cleaved caspase-3 immunoreactivity
in explant cultures of CRLM
Curcumin alone signiﬁcantly decreased proliferation, as reﬂected by
Ki67 staining, and increased apoptosis in 3/8 and 5/8 explants, respec-
tively, when compared to DMSO (sample staining and quantiﬁcation
shown in Fig. 2). The combination of oxaliplatin + curcumin appeared
most eﬃcacious, signiﬁcantly decreasing proliferative index in 6/8 and
inducing apoptosis in 8/8 explants (Table 1).
No treatment-induced changes to XRCC1, ERCC1, MLH1, MSH2
or MSH6 were observed in any samples (Supplemental data S3).
Design of clinical study
The phase I dose escalation trial was designed to comprise three
tiers differing in daily curcumin dose (0.5, 1 or 2 g). Three partici-
pants recruited to tier 1 completed 2 cycles of chemotherapywithout
curcumin-related toxicity, fulﬁlling the criteria for recruitment to
the second tier. Likewise, dose-escalation to the third tier began after
3 patients from tier 2 had completed 2 cycles of chemotherapy
without curcumin-induced toxicities. One patient from the initial
three recruited into tier 3 experienced diarrhoea, which was deemed
to be related to curcumin. Therefore three further patients (6 in total)
were entered into, and completed tier 3 (2 g curcumin daily). Fifty
percent of patients completed 12 cycles of chemotherapy with
curcumin. The average compliance rate (as determined by re-
turned curcumin capsules) across all participants was 93.8%.
Comparing the 3 tiers, mean compliance rates were 84, 100 and 96%
for tiers 1, 2 and 3, respectively. Five patients (41.7%) were 100%
compliant.
Clinical effects of curcumin alone or in combination with FOLFOX
chemotherapy
Side effects: Initially curcumin was administered as a single agent
for one week prior to commencing chemotherapy. Five of twelve
participants (41.7%) experienced no curcumin-induced adverse
events (AE) during the week pre-chemotherapy. The most common
curcumin-induced side effects were constipation (25.0%), dry mouth
(16.7%) and ﬂatulence (16.7%). All AEs reported were grade 2 or less
and did not prevent patients from progressing to chemotherapy. Once
participants received chemotherapy in combination with curcumin,
the most commonly reported side effect was peripheral neuropa-
thy, noted in eleven patients (91.7%). Other toxicities were fatigue
(83.3%), diarrhoea (66.7%) and oral mucositis (58.3%). AEs possibly
attributable to curcumin, but which are also common side effects
of chemotherapy, are shown in Table 2, and appeared unrelated to
curcumin dose (grade 3 AEs as percent total for Tier 1 = 16%; Tier
2 = 6%; Tier 3 = 7% total). The majority of AEs (90.0%) were classed
as grade 1 or 2. Three patients described grade 3 toxicities that could
have been attributed to curcumin. Grade 3 diarrhoea was deemed
dose-limiting for one patient, therefore the curcumin dose was de-
escalated from 2 grams, and maintained at 1 gram. Other grade 3
toxicities, likely unrelated to curcumin, included hyponatraemia, neu-
tropenia, thromboembolic events, urinary tract infections andweight
loss. One grade 5 event occurred where a patient was admitted with
a severe chest infection and subsequently died. This event was not
deemed to be due to curcumin.
Disease response
Eleven of twelve participants (91.7%) showed stable disease or
partial response to treatment after 6 cycles of chemotherapy. A re-
duction in target lesions of at least 30% (partial response) was
recorded in more than half of patients (58.3%), with the best re-
sponse being a 75.8% reduction. At the end of treatment, eight of
the remaining ten participants (80%) maintained a partial re-
sponse or stable disease. Median progression-free survival was 34
weeks. EORTC QLQ30 global health and functionality scores sug-
gested worsening treatment-induced symptoms, but increased
functionality post trial compared with pre-trial scores (Supplemen-
tal data S4).
Acceptability of curcumin
It was important to assess patients’ perceptions of curcumin, if
it is to be used as a chemotherapy adjunct in future trials. Most pa-
tients (91.7%) were ‘not at all’ concerned about the once daily dosing
frequency. By treatment end, the majority of patients (72.7%) re-
ported no diﬃculties with capsule number, size or frequency of their
curcumin dose. Potential side-effects of treatment were a minor
concern for 41.7% of patients prior to commencing treatment. By
treatment end, 81.8% had no concerns regarding side-effects from
curcumin (Supplemental data S5).
Discussion
Curcumin has been extensively investigated for potential
chemopreventive or anti-tumour effects in colorectal cancer. Much
of the research has classically focussed on adherent cell lines, or
Table 1
Summary of the effects of treatment combinations on TIC and proliferative markers in explant culture.
Treatment observations TIC marker Curcumin Oxaliplatin + curcumin 5-FU + curcumin Oxaliplatin + 5-FU Triple
More eﬃcacious than DMSO ALDH1A1 4/10 4/10 2/10 2/10 3/10
CD133 3/9 5/9 4/8 3/9 2/7
CD26 1/10 1/8 1/10 1/10 2/10
Nanog 1/9 1/9 1/9 1/9 1/9
Ki67 3/8 6/8 5/8 2/8 4/8
Cleaved caspase-3 5/8 8/8 5/8 7/8 5/8
More eﬃcacious than oxaliplatin + 5-FU ALDH1A1 3/10 3/10 1/10 N/A 2/10
CD133 3/9 4/9 3/8 N/A 1/7
CD26 0/10 0/8 0/10 N/A 1/10
Nanog 2/9 2/9 2/9 N/A 1/9
Ki67 0/8 3/8 1/8 N/A 0/8
Cleaved caspase-3 2/8 2/8 1/8 N/A 2/8
CD133, ALDH1A1, CD26 and Nanog expressions were assessed following treatment with combinations of curcumin, oxaliplatin and 5-FU. A pathologist, blinded to the treat-
ment groups, assessed expression of TIC markers. Samples were scored using a semi-quantitative +, ++ and +++ grading system based on staining intensity and number of
stained cells. Samples were counted as “more eﬃcacious” if it was at least a single ‘+’ sign less than that for the DMSO or FOLFOX groups. For ki67 and cleaved caspase-3,
absolute numbers of positively stained cells were counted in each treatment group. All data were tested for normality prior to applying a paired sample T test. For samples
exhibiting both normally and non-normally distributed data across treatments, parametric and non-parametric T tests were applied appropriately.
N/A = not applicable.
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Fig. 2. Example ki67 and cleaved caspase-3 scoring of explant immunostaining (A) and sample explant micrographs immunostained for ki67 (B). (A) Normally distributed
data are displayed as red dots, black error bars, the average and the standard deviation. Non-normally distributed data are displayed as black dots with blue error bars.
Signiﬁcant differences are indicated where * represents P ≤ 0.05 compared to DMSO, # corresponds to P ≤ 0.05 compared to OX + 5-FU. Each data point represents an average
score from one ﬁeld of view. Scoring was undertaken by 2 independent observers, and the scores averaged. (B) Sample ki67 explant micrographs shown at ×40 objective.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Treatment side effects.




Abdominal pain 4 33.3% 1,2 1,2,3 1 16.7%
Acute kidney injury 1 8.3% – 1,3 1 33.3%
Anorexia 4 33.3% – 2,3 3 75.0%
Bloating 1 8.3% 2 – – –
Constipation 5 41.7% 1 1,2 – –
Diarrhoea 8 66.7% 1 1,2,3 2 30.8%
Dry mouth 3 25.0% 1 1 – –
Dyspepsia 4 33.3% 1 2 – –
Flatulence 3 25.0% 1 2 – –
Oral mucositis 7 58.3% – 1,2,3 2 16.7%
Nausea 4 33.3% 1 1,2,3 1 16.7%
Rash 2 16.7% – 1,2 – –
Vomiting 2 16.7% – 1,2 – –
Weight loss 4 33.3% – 1,2,3 1 20.0%
Side effects may have been attributable to curcumin, when given in combination with FOLFOX chemotherapy.
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use of animal models exhibiting APC loss [4,29–32]. The discovery
of novel anticancer therapies now preferentially involves the use
of models which have greater resemblance to clinical disease [33–35],
primarily by utilising tissues resected from patients. This allows study
of drug action across the heterogenous phenotypic/genotypic cohorts
representative of the malignancy under study. CRLM models have
thus far rarely been used to study the eﬃcacy of chemotherapy
agents in colorectal cancer. Cancer stem cells are increasingly prof-
fered as a target to prevent disease recurrence or to circumvent
therapeutic resistance. Therefore, regimens which may be able to
target both the rapidly proliferating differentiated cells concur-
rent with less frequently dividing stem-like cells may improve overall
therapeutic eﬃcacy. We and others have utilised the established
colorectal cancer cell lines HCT-116 and HT-29 to assess potential
for the curcumin/oxaliplatin/5-FU combinations to down-regulate
the stem-like phenotype [4,36–39]. Curcumin alone and in com-
bination with chemotherapy was observed to inhibit spheroid
formation and downregulate stem cell associatedmarkers CD44 and
CD166 and ALDH activity, in addition to downregulation of epider-
mal growth factor, insulin-like growth factor and Notch, all of which
may have involvement in maintenance of the stem-like pheno-
type. Following on from this data, it was essential to translate these
ﬁndings to models with greater relevance to colorectal cancer pa-
tients. The ﬁndings presented here suggest for the ﬁrst time that
curcumin may enhance oxaliplatin/5-FU-based chemotherapy in
models derived directly from patients for whom the treatments are
ultimately intended. The observed reduction of spheroid number
by the combination of 5-FU/oxaliplatin +curcumin is indicative of
the ability of this combination to affect the cancer stem cell pop-
ulation. In addition, curcumin alone decreased spheroid number to
a greater extent than the 5-FU/oxaliplatin treatments. Previously
we have shown that spheroid forming capacity in CRLM is re-
ﬂected by the order of expression of ALDHhigh > CD133 > CD26 [26].
This order suggests that reduction in ALDH activity correlates with
reduced spheroids and fewer CSCs [26]. Transcription factors as-
sociated with the ALDHhigh stem-like phenotype (Oct 3/4, Nanog,
Otx2, AFP) were also downregulated by the combination of 5-FU/
oxaliplatin + curcumin. Explant cultures corroborated that com-
binations including curcumin were able to decrease CSC markers
when compared to oxaliplatin + 5-FU for ALDH, CD133 and Nanog.
Differential treatment responses were not due to donor differ-
ences in expression of proteins associated with 5-FU resistance
(XRCC1, ERCC, MLH1, MSH2 or MSH6) [40,41] (Supplemental data
S3).
There has been much speculation as to whether curcumin may
prove a suitable adjunct to chemotherapy in clinical regimens, and
here we established that combination of curcuminwith FOLFOX che-
motherapy in CRLM patients was safe and tolerable in the ﬁrst line
setting. Patients generally tolerated their week of curcumin (pre-
chemotherapy) with minimal AEs. The events reported were
primarily gastrointestinal and consistent with those described in
previous curcumin trials [3]. Side-effects were mild (Grade 1 or 2),
either resolving spontaneously or following medication. Addition
of curcumin to FOLFOX was well tolerated, with a compliance rate
of 93.8%. Increasing curcumin dose did not affect compliance, which
was in keeping with other oral antineoplastic agents such as
Tamoxifen and Capecitabine (median compliance rates of 72–96%,
86.7–100% respectively) [42,43]. Diarrhoea was the main serious
adverse event possibly associated with curcumin. Diarrhoea is com-
monly observed in patients treated with the combination of FOLFOX
and Bevacizumab (11%) [44], and FOLFOX alone, with grade 3–4 di-
arrhoea reported in 10% of patients [45]. It was therefore diﬃcult
to determine howmuch each treatment component contributed to
the grade 3 diarrhoea observed in two patients here.
Median PFS and treatment response were largely comparable
with that previously reported for FOLFOX and FOLFOX + Bevacizumab
[46], although it is important to note that the limited patient
numbers in this study do not permit conclusions to be drawn re-
garding potential eﬃcacy. Whilst approximately 55% of trial
participants reported deterioration in their therapy-induced symp-
toms by the end of their treatment, the majority (72.7%) reported
that they would be willing to continue curcumin for as long as was
necessary. This reﬂected the perception by participants that most
of their side-effects were due to chemotherapy, resulting in
favourable opinions on tolerability and feasibility of this treatment.
This study reports for the ﬁrst time that addition of curcumin
to FOLFOX-based chemotherapy enhances eﬃcacy in patient-
derived CRLM cultures. Greater pro-apoptotic and CSC targeting
eﬃcacy was observed for curcumin than for oxaliplatin and 5-FU
in a small patient subset, warranting further investigation to de-
termine factors that inﬂuence response to curcumin. For the ﬁrst
time, safety and tolerability for curcumin in combination with
FOLFOX chemotherapy are reported. A randomised phase II study
comparing participants receiving FOLFOX only with those receiv-
ing FOLFOX + curcumin is currently recruiting.
Funding
This work was supported by two studentships fromHope Against
Cancer, Leicester, UK, The Royal College of Surgeons (Eng), The Bowel
Disease Research Foundation, by Cancer Research UK on a pro-
gramme grant [C325/A13101] and by Cancer Research UK in
conjunction with the Department of Health on an Experimental
Cancer Medicine Centre grant [C325/A15575].
Authors’ contributions
MIJ: Ex vivo laboratory work, manuscript preparation; CI: re-
cruitment and monitoring of patients in phase I, regulatory
paperwork, manuscript preparation; GI: study design, original reg-
ulatory and ethics submissions, obtained funding; AK: ex vivo
laboratory work; JAH: ﬂow cytometry; NG-T: patient recruitment;
AT: study design, patient recruitment, manuscript preparation; PG:
pathology; HC: in vivo work; SRP: sample collection and process-
ing; BM: radiology input; AD, MM, GG, DML: surgical input,
manuscript preparation; DPB: surgical input, ethics submission (ex
vivo), manuscript preparation; WPS study design, ethics submis-
sion, obtained funding, manuscript preparation; LMH: study design,
obtained funding, managed research, wrote manuscript; KB: study
design, obtained funding, manuscript preparation. All authors read
and approved the ﬁnal manuscript.
Acknowledgements
We would like to thank Dr M. Viskaduraki of the University of
Leicester Bioinformatics and Biostatistics Hub for input on statis-
tical analyses, and Prof A Gescher for his insight during the




Supplementary data to this article can be found online at
doi:10.1016/j.canlet.2015.05.005.
References
[1] Excellence NIfC. Colorectal cancer: the diagnosis and management of colorectal
cancer. <http://www.nice.org.uk/Guidance/CG131>, 2011.
140 M.I. James et al./Cancer Letters 364 (2015) 135–141
[2] National Cancer Institute, National Cancer Institute: colon cancer treatment.
<http://cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional>, 2014
(accessed 13.05.14).
[3] G.R. Irving, A. Karmokar, D.P. Berry, et al., Curcumin: the potential for eﬃcacy
in gastrointestinal diseases, Best Pract. Res. Clin. Gastroenterol. 25 (4–5) (2011)
519–534.
[4] L.M. Howells, S. Sale, S.N. Sriramareddy, et al., Curcumin ameliorates oxaliplatin-
induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo,
Int. J. Cancer 129 (2) (2011) 476–486.
[5] G.R. Irving, L.M. Howells, S. Sale, et al., Prolonged biologically active colonic tissue
levels of curcumin achieved after oral administration – a clinical pilot study
including assessment of patient acceptability, Cancer Prev. Res. 6 (2) (2013)
119–128.
[6] B. Kim, F.M. Giardiello, Chemoprevention in familial adenomatous polyposis,
Best Pract. Res. Clin. Gastroenterol. 25 (4–5) (2011) 607–622 [Epub 2011/11/30].
[7] R.E. Carroll, R.V. Benya, D.K. Turgeon, et al., Phase IIa clinical trial of curcumin
for the prevention of colorectal neoplasia, Cancer Prev. Res. 4 (3) (2011)
354–364.
[8] G. Garcea, D.P. Berry, D.J. Jones, et al., Consumption of the putative
chemopreventive agent curcumin by cancer patients: assessment of curcumin
levels in the colorectum and their pharmacodynamic consequences, Cancer
Epidemiol. Biomarkers Prev. 14 (1) (2005) 120–125.
[9] G. Garcea, D.J. Jones, R. Singh, et al., Detection of curcumin and its metabolites
in hepatic tissue and portal blood of patients following oral administration,
Br. J. Cancer 90 (5) (2004) 1011–1015.
[10] Z.Y. He, C.B. Shi, H. Wen, et al., Upregulation of p53 expression in patients with
colorectal cancer by administration of curcumin, Cancer Invest. 29 (3) (2011)
208–213.
[11] R.A. Sharma, S.A. Euden, S.L. Platton, et al., Phase I clinical trial of oral curcumin:
biomarkers of systemic activity and compliance, Clin. Cancer Res. 10 (20) (2004)
6847–6854.
[12] N. Dhillon, B.B. Aggarwal, R.A. Newman, et al., Phase II trial of curcumin in
patients with advanced pancreatic cancer, Clin. Cancer Res. 14 (14) (2008)
4491–4499.
[13] R. Epelbaum, M. Schaffer, B. Vizel, et al., Curcumin and gemcitabine in patients
with advanced pancreatic cancer, Nutr. Cancer 62 (8) (2010) 1137–1141.
[14] M. Kanai, Y. Otsuka, K. Otsuka, et al., A phase I study investigating the safety
and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer
patients, Cancer Chemother. Pharmacol. 71 (6) (2013) 1521–1530.
[15] M. Kanai, K. Yoshimura, M. Asada, et al., A phase I/II study of gemcitabine-based
chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic
cancer, Cancer Chemother. Pharmacol. 68 (1) (2011) 157–164.
[16] M. Bayet-Robert, F. Kwiatkowski, M. Leheurteur, et al., Phase I dose escalation
trial of docetaxel plus curcumin in patients with advanced andmetastatic breast
cancer, Cancer Biol. Ther. 9 (1) (2010) 8–14.
[17] V.S. Ghalaut, L. Sangwan, K. Dahiya, et al., Effect of imatinib therapy with and
without turmeric powder on nitric oxide levels in chronic myeloid leukemia,
J. Oncol. Pharm. Pract. 18 (2) (2012) 186–190.
[18] T. Golombick, T.H. Diamond, V. Badmaev, et al., The potential role of curcumin
in patients with monoclonal gammopathy of undeﬁned signiﬁcance – its effect
on paraproteinemia and the urinary N-telopeptide of type I collagen bone
turnover marker, Clin. Cancer Res. 15 (18) (2009) 5917–5922.
[19] G. Belcaro, M. Hosoi, L. Pellegrini, et al., A controlled study of a lecithinized
delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer
treatment, Phytother. Res. 28 (3) (2014) 444–450.
[20] J.L. Ryan, C.E. Heckler, M. Ling, et al., Curcumin for radiation dermatitis: a
randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer
patients, Radiat. Res. 180 (1) (2013) 34–43.
[21] L. Norris, A. Karmokar, L. Howells, et al., The role of cancer stem cells in the
anti-carcinogenicity of curcumin, Mol. Nutr. Food Res. 57 (9) (2013) 1630–1637
[Epub 2013/08/01].
[22] C. Kantara, M. O’Connell, S. Sarkar, et al., Curcumin promotes autophagic survival
of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA, Cancer
Res. 74 (9) (2014) 2487–2498 [Epub 2014/03/15].
[23] H. Zhang, T. Yu, L. Wen, et al., Curcumin enhances the effectiveness of cisplatin
by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment, Exp.
Ther. Med. 6 (5) (2013) 1317–1321 [Epub 2013/11/14].
[24] B. Bao, A. Ahmad, A.S. Azmi, et al. Overview of cancer stem cells (CSCs) and
mechanisms of their regulation: implications for cancer therapy. Current
protocols in pharmacology/editorial board, SJ Enna. 2013;Chapter 14:Unit 14
25. [Epub 2013/06/08].
[25] W.M. Elshamy, R.J. Duhe, Overview: cellular plasticity, cancer stem cells and
metastasis, Cancer Lett. 341 (1) (2013) 2–8 [Epub 2013/06/26].
[26] M.I. James, L.M. Howells, A. Karmokar, et al., Characterization and propagation
of tumor initiating cells derived from colorectal liver metastases: trials,
tribulations and a cautionary note, PLoS ONE 10 (2) (2015) e0117776.
[27] A.W. Chan, J.M. Tetzlaff, D.G. Altman, et al., SPIRIT 2013 statement: deﬁning
standard protocol items for clinical trials, Ann. Intern. Med. 158 (3) (2013)
200–207.
[28] G. Irving, C. Iwuji, B. Morgan, et al., Combining curcumin (C3-complex, Sabinsa)
with standard care FOLFOX chemotherapy in patients with inoperable colorectal
cancer (CUFOX): study protocol for a randomised control trial, Trials 16 (2015)
110.
[29] S. Perkins, R.D. Verschoyle, K. Hill, et al., Chemopreventive eﬃcacy and
pharmacokinetics of curcumin in the min/+ mouse, a model of familial
adenomatous polyposis, Cancer Epidemiol. Biomarkers Prev. 11 (6) (2002)
535–540.
[30] C. Pettan-Brewer, J. Morton, R. Mangalindan, et al. Curcumin suppresses
intestinal polyps in APCMinmice fed a high fat diet. Pathobiol. Aging Age Relat.
Dis. (2011) 1.
[31] A. Shehzad, J. Lee, T.L. Huh, et al., Curcumin induces apoptosis in human
colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53,
Mol. Cells 35 (6) (2013) 526–532.
[32] L.M. Howells, A. Mitra, M.M. Manson, Comparison of oxaliplatin- and curcumin-
mediated antiproliferative effects in colorectal cell lines, Int. J. Cancer 121 (1)
(2007) 175–183.
[33] S. Commandeur, F.R. de Gruijl, R. Willemze, et al., An in vitro three-dimensional
model of primary human cutaneous squamous cell carcinoma, Exp. Dermatol.
18 (10) (2009) 849–856.
[34] K.E. Hovinga, F. Shimizu, R. Wang, et al., Inhibition of notch signaling in
glioblastoma targets cancer stem cells via an endothelial cell intermediate, Stem
Cells 28 (6) (2010) 1019–1029.
[35] F. Shimizu, K.E. Hovinga, M. Metzner, et al. Organotypic explant culture of
glioblastoma multiforme and subsequent single-cell suspension. Current
protocols in stem cell biology. 2011;Chapter 3:Unit3 5.
[36] S.S. Kanwar, Y. Yu, J. Nautiyal, et al., Diﬂuorinated-curcumin (CDF): a novel
curcumin analog is a potent inhibitor of colon cancer stem-like cells, Pharm.
Res. 28 (4) (2011) 827–838.
[37] B.B. Patel, D. Gupta, A.A. Elliott, et al., Curcumin targets FOLFOX-surviving colon
cancer cells via inhibition of EGFRs and IGF-1R, Anticancer Res. 30 (2) (2010)
319–325.
[38] B.B. Patel, R. Sengupta, S. Qazi, et al., Curcumin enhances the effects of
5-ﬂuorouracil and oxaliplatin in mediating growth inhibition of colon cancer
cells by modulating EGFR and IGF-1R, Int. J. Cancer 122 (2) (2008) 267–273.
[39] Y. Yu, S.S. Kanwar, B.B. Patel, et al., Elimination of colon cancer stem-like cells
by the combination of curcumin and FOLFOX, Transl. Oncol. 2 (4) (2009)
321–328.
[40] F.A. Sinicrope, DNA mismatch repair and adjuvant chemotherapy in sporadic
colon cancer, Nat. Rev. Clin. Oncol. 7 (3) (2010) 174–177.
[41] H.C. Kwon, M.S. Roh, S.Y. Oh, et al., Prognostic value of expression of ERCC1,
thymidylate synthase, and glutathione S-transferase P1 for 5-ﬂuorouracil/
oxaliplatin chemotherapy in advanced gastric cancer, Ann. Oncol. 18 (3) (2007)
504–509.
[42] A.H. Partridge, J. Avorn, P.S. Wang, E.P. Winer, Adherence to therapy with oral
antineoplastic agents, J. Natl Cancer Inst. 94 (9) (2002) 652–661.
[43] L. Krolop, Y.D. Ko, P.F. Schwindt, et al., Adherence management for patients with
cancer taking capecitabine: a prospective two-arm cohort study, BMJ Open 3
(7) (2013).
[44] C.J. Allegra, G. Yothers, M.J. O’Connell, et al., Initial safety report of NSABP C-08:
a randomized phase III study of modiﬁed FOLFOX6 with or without
bevacizumab for the adjuvant treatment of patients with stage II or III colon
cancer, J. Clin. Oncol. 27 (20) (2009) 3385–3390.
[45] C. Tournigand, T. Andre, E. Achille, et al., FOLFIRI followed by FOLFOX6 or the
reverse sequence in advanced colorectal cancer: a randomized GERCOR study,
J. Clin. Oncol. 22 (2) (2004) 229–237.
[46] L.B. Saltz, S. Clarke, E. Diaz-Rubio, et al., Bevacizumab in combination with
oxaliplatin-based chemotherapy as ﬁrst-line therapy in metastatic colorectal
cancer: a randomized phase III study, J. Clin. Oncol. 26 (12) (2008) 2013–2019.
141M.I. James et al./Cancer Letters 364 (2015) 135–141
